Breaking News
December 15, 2017 - Researchers identify potential alternatives to tackle drug resistant malaria parasites
December 15, 2017 - Scientists unravel mystery of how immune cells remember infections decades later
December 15, 2017 - Outcomes Poorer for Black Patients with Early Breast Ca
December 15, 2017 - Liposuction May Ease Limb Swelling in Cancer Patients
December 15, 2017 - How well can digital assistants answer questions on sex?
December 15, 2017 - NIH-funded study to explore hearing loss risk in Detroit firefighters
December 15, 2017 - Caris Life Sciences reveals identification of new mechanism of action to treat NHL
December 15, 2017 - Loyola Medicine study finds high success rate for diabetic Charcot foot surgery
December 15, 2017 - Bone marrow edema does not increase due to intense physical activity, study finds
December 15, 2017 - Human ‘common cold’ virus kills healthy chimpanzees in Uganda
December 15, 2017 - Experience of reflex walking refines perception of biological motion during early infancy
December 15, 2017 - FDA Approves Admelog (insulin lispro) Rapid-Acting “Follow-On” Insulin Product to Treat Diabetes
December 14, 2017 - Friday Feedback: Good Idea for Ex-Pharma Exec to Run HHS?
December 14, 2017 - More than 200 people sickened onboard Ovation of Seas cruise
December 14, 2017 - FDA announces new approach for sharing updates on antibiotics, antifungal drugs to physicians
December 14, 2017 - Steroid study provides new insights into medicines’ side effects
December 14, 2017 - Government announces plans to include eye test reminder during driving license renewal
December 14, 2017 - Non-ionizing radiation from magnetic fields could have adverse biological impacts on health
December 14, 2017 - Bi-annual MRI beats mammograms in detecting breast cancer among women with genetic risk
December 14, 2017 - Researchers develop new method for quickly detecting signs of multiple sclerosis
December 14, 2017 - In era of increased competition, hospitals fret over ratings
December 14, 2017 - Female veterans experience improvement in low back pain with course of chiropractic care
December 14, 2017 - Relieving Symptoms of Cystic Fibrosis with Exercise
December 14, 2017 - FDA Alert: Blue Pearl All Natural Male Enhancement Supplement: Recall
December 14, 2017 - CardioBrief: In Defense Of ORBITA
December 14, 2017 - Definition of High Blood Pressure Drops: MedlinePlus Health News
December 14, 2017 - Drug may help surgical patients stop opioids sooner
December 14, 2017 - Researchers develop biosensor that enables development of new health tests
December 14, 2017 - Radiation therapy can be used to treat patients with life-threatening heart rhythm
December 14, 2017 - UVA researchers developing tool to help prostate cancer patients weigh treatment options
December 14, 2017 - Experts tell Congress how to cut drug prices
December 14, 2017 - Researchers use cryptographic techniques to decode activity of motor neurons
December 14, 2017 - Study finds changes in the heart after spinal cord injury
December 14, 2017 - Health Highlights: Dec. 12, 2017
December 14, 2017 - Pelzman’s Picks: How States Can Cut Disparities in Care and Costs
December 14, 2017 - New Hemophilia Treatment Stems Bleeding Episodes: MedlinePlus Health News
December 14, 2017 - Onetime ‘world’s heaviest man’ has second surgery in Mexico
December 14, 2017 - Belgian researchers create transplantable artificial ovary prototype
December 14, 2017 - Using atraumatic needles for lumbar punctures decreases risk of complications
December 14, 2017 - Outpatient total knee replacement surgery linked to higher rates of complications
December 14, 2017 - Social impairments can be corrected by brain stimulation
December 14, 2017 - Studies reveal possibility for memory T cells to serve a dual purpose
December 14, 2017 - Antibody-Drug Conjugate Ups PFS in Untreated Hodgkin’s
December 14, 2017 - Study finds reading information aloud to yourself improves memory
December 14, 2017 - Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Hydraulic fracturing is harmful to infants health, study states
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - People diagnosed with schizophrenia or bipolar disorder may actually have treatable condition
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - Good friends might be your best brain booster as you age
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder

FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder

image_pdfDownload PDFimage_print
Treatment for Opiate Dependence

FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder

Slough, UK and Richmond, VA, 31 October 2017– Indivior PLC (LON: INDV) announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 18 to 1 to recommend approval of RBP-6000 for the treatment of opioid use disorder (OUD). RBP-6000 is an investigational once-monthly injectable buprenorphine formulation in the ATRIGEL® delivery system for the treatment of adults with moderate-to-severe OUD, as part of a complete treatment plan to include counseling and psychosocial support.

“The Advisory Committees’ favorable recommendation of RBP-6000 moves us one step closer to potentially bringing this once-monthly injectable buprenorphine treatment option to patients struggling with opioid use disorder,” said Shaun Thaxter, Chief Executive Officer of Indivior. “We are committed to pioneering new options for patients living with this chronic, yet treatable disease to help address the nation’s growing opioid epidemic.”

The FDA will consider the Advisory Committees’ non-binding recommendation in its review of the New Drug Application for RBP-6000 that was submitted by Indivior on May 30, 2017. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2017.

About RBP-6000

RBP-6000 IS AN INVESTIGATIONAL PRODUCT WHOSE SAFETY AND EFFICACY ARE BEING EVALUATED BY THE U.S. FOOD AND DRUG ADMINISTRATION.

RBP-6000 is an investigational buprenorphine sustained-release formulation using the ATRIGEL® delivery system, which consists of a polymeric solution of a biodegradable poly-(DL-lactide-co-glycolide) co-polymer dissolved in N-methyl pyrrolidone (NMP), a water-miscible biocompatible solvent. After subcutaneous injection, NMP diffuses out of the polymer matrix and the polymer precipitates, trapping buprenorphine inside and forming an amorphous solid depot in situ. The depot releases buprenorphine over a one-month period by diffusion as the polymer biodegrades.

The Phase 3 study met its primary efficacy endpoint, with both RBP-6000 dosage regimens demonstrating abstinence rates that were significantly higher versus placebo (300 mg/300 mg: 41.3%; 300 mg/100 mg: 42.7%; placebo: 5.0%, p

About Opioid Use Disorder

According to the DSM–51, opioid use disorder is characterized by signs and symptoms that reflect compulsive, prolonged self-administration of opioid substances that are used for no legitimate medical purpose or, if another medical condition is present that requires opioid treatment, they are used in doses greatly in excess of the amount needed for that medical condition.

Based on 2016 data from the most recent National Survey on Drug Use and Health report, 11.8 million Americans engaged in misuse of opioids in the last year. Approximately 2 million American adults (age 12+ years old) met criteria for opioid use disorder in the past year. The same report suggested that 935,000 adults have used heroin in the past year and 471,000 used in the past month. There were approximately 625,000 adults who had a heroin use disorder in the past year2.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Forward-Looking Statements

This press release contains certain statements that are forward-looking and which should be considered, amongst other statutory provisions, in light of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve risk and uncertainty as they relate to events or circumstances that will or may occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Forward-looking statements include, among other things, statements regarding our financial guidance for 2017 and our medium- and long-term growth outlook, our operational goals, our product development pipeline and statements regarding ongoing litigation.

Various factors may cause differences between Indivior’s expectations and actual results, including: factors affecting sales of Indivior Group’s products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group’s drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to legal proceedings; the Indivior Group’s ability to protect its patents and other intellectual property; the outcome of patent infringement litigation relating to Indivior Group’s products, including the ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

This press release does not constitute an offer to sell, or the solicitation of an offer to subscribe for or otherwise acquire or dispose of shares in the Company to any person in any jurisdiction to whom it is unlawful to make such offer or solicitation.

Source: Indivior PLC

Posted: October 2017

Related Articles

RBP-6000 (buprenorphine) FDA Approval History

Tagged with:

About author

Related Articles